Caribou Biosciences, Inc. Variable Lease, Cost
Caribou Biosciences, Inc. (CRBU) reported Variable Lease, Cost of $2.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-05
- Caribou Biosciences, Inc. variable lease, cost for the quarter ending 2024-12-31 was $500.00K, a 16.67% decline year-over-year.
- Caribou Biosciences, Inc. variable lease, cost for the quarter ending 2024-09-30 was $700.00K, a 0.00% change year-over-year.
- Caribou Biosciences, Inc. variable lease, cost for the quarter ending 2024-06-30 was $600.00K, a 0.00% change year-over-year.
- Caribou Biosciences, Inc. variable lease, cost for the quarter ending 2024-03-31 was $700.00K, a 16.67% increase year-over-year.
- Caribou Biosciences, Inc. variable lease, cost for fiscal 2025 was $2.80M, a 12.00% increase from fiscal 2024.
- Caribou Biosciences, Inc. variable lease, cost for fiscal 2024 was $2.50M, a 0.00% change from fiscal 2023.
- Caribou Biosciences, Inc. variable lease, cost for fiscal 2023 was $2.50M, a 13.64% increase from fiscal 2022.
- Caribou Biosciences, Inc. variable lease, cost for fiscal 2022 was $2.20M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.80M 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.20M derived: sum of 2 quarters · filed 2026-03-05 | $1.80M derived: sum of 3 quarters · filed 2026-03-05 | $2.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | $700.00K 10-Q · filed 2024-11-06 | $1.30M derived: sum of 2 quarters · filed 2024-11-06 | $2.00M 10-Q · filed 2024-11-06 | $2.60M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | $600.00K 10-Q · filed 2024-08-06 | $1.30M 10-Q · filed 2024-08-06 | $1.90M derived: sum of 3 quarters · filed 2025-03-10 | $2.60M derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | $700.00K 10-Q · filed 2024-05-07 | $1.30M derived: sum of 2 quarters · filed 2025-03-10 | $2.00M derived: sum of 3 quarters · filed 2025-03-10 | $2.60M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.30M derived: sum of 2 quarters · filed 2025-03-10 | $1.90M derived: sum of 3 quarters · filed 2025-03-10 | $2.50M 10-K · filed 2025-03-10 |
| 2023-09-30 | $700.00K 10-Q · filed 2024-11-06 | $1.30M derived: sum of 2 quarters · filed 2024-11-06 | $1.90M 10-Q · filed 2024-11-06 | $2.50M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $600.00K 10-Q · filed 2024-08-06 | $1.20M 10-Q · filed 2024-08-06 | $1.80M derived: sum of 3 quarters · filed 2024-08-06 | $2.40M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-07 | $1.20M derived: sum of 2 quarters · filed 2024-05-07 | $1.80M derived: sum of 3 quarters · filed 2024-05-07 | $2.30M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.20M derived: sum of 2 quarters · filed 2024-03-11 | $1.70M derived: sum of 3 quarters · filed 2024-03-11 | $2.20M 10-K · filed 2024-03-11 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-07 | $1.10M derived: sum of 2 quarters · filed 2023-11-07 | $1.60M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-08 | $1.00M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |